泰恩康：全资子公司利多卡因丙胺卡因气雾剂收到药品注册受理通知书

Core Viewpoint - The company announced that its wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., has received the acceptance notice for the registration application of Lidocaine Prilocaine aerosol from the National Medical Products Administration of China [1] Group 1 - The National Medical Products Administration has reviewed and accepted the drug registration application for the aerosol product [1] - The acceptance is based on the provisions of Article 32 of the Administrative Licensing Law of the People's Republic of China [1]